Prospective Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of ERCC1 in Response to Treatment With Neoadjuvant Radiochemotherapy in Patients With Esophageal Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic
histopathologic response to chemoradiation
Patients with cT3 esophageal cancer received RTx/CTx according a standardized protocol. 6 weeks after this neoadjuvant therapy a tranthoracic esophagectomy with two-field lymphadenectomy will be performed. The histopathologic response is measured using the surgical specimen.
1 month postoperative
No
Arnulf H. Hölscher, MD
Principal Investigator
Department of General, Visceral and Cancer Surgery, University of Cologne
Germany: Ethics Commission
UK-09-118
NCT00953511
August 2009
March 2013
Name | Location |
---|